Molecular Docking in Formulation and Development

Author(s): Tejinder Kaur*, Ashwini Madgulkar, Mangesh Bhalekar, Kalyani Asgaonkar.

Journal Name: Current Drug Discovery Technologies

Volume 16 , Issue 1 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: In pharmaceutical research drug discovery and development process is timeconsuming and expensive. In many cases, it produces incompetent results due to the failure of in vitro and in vivo conventional approaches. Before any new drug is placed in the market it must undergo rigorous testing to get FDA approval. Due to the several limitations imposed by the drug discovery process, in recent times in silico approaches are widely applied in this field. The purpose of this review is to highlight the current molecular docking strategies used in drug discovery and to explore various advances in the field.

Methods: In this review we have compiled database after an extensive literature search on docking studies which has found its applications relevant to the field of formulation and development. The papers retrieved were further screened to appraise the quality of work. In depth strategic analysis was carried out to confirm the credibility of the findings.

Results: The papers included in this review highlight the promising role of docking studies to overcome the challenges in formulation and development by emphasizing it’s applications to predict drug excipient interactions which in turn assist to increase protein stability; to determine enzyme peptide interactions which maybe further used in drug development studies; to determine the most stable drug inclusion complex; to analyze structure at molecular level that ascertain an increase in solubility, dissolution and in turn the bioavailability of the drug; to design a dosage form that amplify the drug discovery and development process.

Conclusion: This review summarizes recent findings of critical role played by molecular docking in the process of drug discovery and development. The application of docking approach will assist to design a dosage form in the most cost effective and time saving manner.

Keywords: Molecular modelling, drug discovery, molecular docking, formulation and development, pharmaceutical research, molecular modeling.

[1]
Morris GM, Lim-Wilby M. Molecular docking. Methods Mol Biol 2008; 443: 365-82.
[2]
Satya G. QSAR and molecular modelling Anamaya publisher: 2010; 52-53,97,98.
[3]
Venkateshan N, Selvakumar D. Molecular docking studies: An overview. WJPPS 2016; 5(1): 1411-5.
[4]
Monika G, Gaba P, Singh S. An overview on molecular docking. Int J Drug Dev Res 2010; 2(2): 219-31.
[5]
Mukesh B. Molecular docking-a review. IJRAP 2011; 2(6): 1746-51.
[6]
Wendy DC. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 1995; 117(19): 5179-97.
[7]
Bernard RB. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 1983; 14(2): 187-217.
[8]
Friesner RA. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004; 47(7): 1739-49.
[9]
Harren J, Andrew L. Structure based drug discovery, springer publisher. 1st Edn . 2007; pp. 229-30.
[10]
AutoDock. http://autodock.scripps.edu (Accessed Aug 16, 2017)
[11]
Overview of DOCK. http://dock.compbio.ucsf.edu (Accessed Aug 16, 2017).
[12]
GOLD-The Cambridge Crystallographic Data Centre (CCDC). http://ccdc.cam.ac.uk/solutions/csd-discovery/components/gold/ (Accessed Dec 16, 2017)
[13]
Molecular Docking Software. http://vlifesciences.com (Accessed Aug 17, 2017).
[14]
Maestro Schrodinger. http://www.schrodinger.com (Accessed Aug 17, 2017)
[15]
Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 2005; 289(1-2): 1-30.
[16]
Haider ST. Optimum protein-excipient interactions using molecular docking simulations. J Undergraduate Res 2014; pp. 441-6.
[17]
Haider ST, Brock AC. Roughton B, Kyle V Camarda designing optimum protein-excipient interactions using molecular docking simulations. Comp Aided Chem Eng 2014; pp. 69-74.
[18]
Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 1985; 25(7): 849-57.
[19]
Yang JM, Chen CC. Gemdock: A generic evolutionary method for molecular docking. Proteins Struct Funct Bioinform 2004; 55(2): 288-304.
[20]
Teresa SB, Cheng Z, Mire Z, et al. Identification of protein–excipient interaction hotspots using computational approaches. Int J Mol Sci 2016; 17: 853.
[21]
Li C, Wang JX, Le Y, Chen JF. Studies of bicalutamide-excipients interaction by combination of molecular docking and molecular dynamics simulation. Mol Pharm 2013; 10: 2362-9.
[22]
Mackay EA, Ehrhard A, Moniatte M, et al. A possible role for cathepsins D, E and B in the processing of P-amyloid precursor protein in Alzheimer’s disease. Eur J Biochem 1997; 244(2): 414-25.
[23]
Maruti JD, Chidambar B, Kailas DS, et al. Homology modeling, molecular docking and MD simulation studies to investigate role of cysteine protease from Xanthomonas campestris in degradation of Aβ peptide. Comput Biol Med 2013; 43(12): 2063-70.
[24]
Melnikova I. Therapies for Alzheimer’s disease. Nat Rev Drug Discov 2007; 6: 341-2.
[25]
Hitzeman N. Cholinesterase inhibitors for Alzheimer’s disease. Am Fam Physician 2006; 74: 747-9.
[26]
Case DA, Cheatham TE, Darden T, et al. The Amber biomolecular simulation programs. J Comput Chem 2005; 26: 1668-88.
[27]
Jiansong F, Ping W, Ranyao Y, et al. Inhibition of acetylcholinesterase by two genistein derivatives: Kinetic analysis, molecular docking molecular dynamics simulation. Acta Pharm Sin B 2014; 4(6): 430-7.
[28]
Perlmann P, Troye-Blomberg M. Malaria blood-stage infection and its control by the immune system. Folia Biol 1999; 46(6): 210-8.
[29]
Trott O. AutoDock Vina, improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 2010; 31: 455-61.
[30]
Md Anayet H, Md Habibul HM, Afrin SC, et al. Molecular-docking study of malaria drug target enzyme transketolase in Plasmodium falciparum 3D7 portends the novel approach to its treatment. Source Code Biol Med 2015; 10: 7.
[31]
Injoon O. Mi-YL, Yong-BL, et al Spectroscopic characterization of ibuprofen/2-hydroxypropyl- ß cyclodextrin inclusion complex. Int J Pharm 1998; 175(2): 215-22.
[32]
Lucret U, Laura S. Physicochemical analysis and molecular modeling of the fosinopril


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 16
ISSUE: 1
Year: 2019
Page: [30 - 39]
Pages: 10
DOI: 10.2174/1570163815666180219112421
Price: $58

Article Metrics

PDF: 41
HTML: 5